immagine del profilo
jkb92
@jkb92
4Mes·

New purchase

I added 20 shares $PODD (+0,88%) to my portfolio. I’m taking advantage of the dip and think the pharma sector could benefit in the next rotation. There have also been notable insider purchases recently. I’m hedging closely. If the recent low doesn’t hold, they’re out again.


@Max095 Thanks for the introduction, although I actually came across the company through CEOWatcher.

immagine del profilo
Maximilian
@Max095
6Mes·

Share presentation from the medical technology sector

🧠 What does Insulet do anyway?


Insulet $PODD (+0,88%) develops the Omnipod system - a tubeless insulin pump for diabetics.


👉 Advantage:


  • No classic tube
  • Easier in everyday life
  • Particularly popular with younger patients



💡 The trend is clearly moving towards automated diabetes therapy (keyword: artificial pancreas)


📊 Figures that are convincing


  • 📈 Sales growth: ~20-30% per year
  • 💰 Turnover: over 1.5+ billion USD
  • 📊 Gross margin: ~65-70%
  • 🌍 Market: growing strongly worldwide (diabetes is on the rise)



👉 Important:

The addressable market is huge and growing every year


🚀 Why could the share continue to rise?


✅ More diabetes patients worldwide

✅ Trend towards modern technology (pumps instead of syringes)

✅ Recurring income (pods have to be constantly repurchased!)

✅ Strong market position in the "tubeless pumps" sector


👉 The business model is almost like a subscription model 💰


⚠️ Risks (of course there are risks)


  • Competition from companies such as DexCom or Medtronic
  • High valuation (not a bargain!)
  • Dependence on innovation & approvals



🧭 My conclusion


👉 Insulet is not a hype play, but rather a long-term growth stock in the healthcare sector

7
Partecipa alla conversazione
IscrivitiAccesso